HROB and prostate adenocarcinoma: PFI analysis also suggested that HROB overexpression may indicate poor prognosis for tumor patients, including ACC (p < 0.001), KIRC (p < 0.001), KIRP (p = 0.002), LIHC (p < 0.001), LUAD (p = 0.002), PAAD (p = 0.019), pheochromocytoma and paraganglioma (PCPG) (p = 0.015), prostate adenocarcinoma (PRAD) (p < 0.001), SKCM (p = 0.031), and THCA (p = 0.044) (Figures 5A–J).